linjc16/ctgov huggingface dataset:
Effects of a Dual Task Protocol on Cognition and Functionality in Non-sedentary Older Adults

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to analyze the effects of a dual task protocol on cognitive domains and functional capacity in non-sedentary older adults. The hypothesis of the present study is that older people undergoing to a dual task exercise protocol have greater benefits on cognition and functional performance, compared to a standard exercise protocol.

Conditions
-----------------
Non-sedentary

Intervention / Treatment
-----------------
* Other: Dual task training
* Other: Conventional training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged over 60 years community people ability to walk alone non-sedentary Exclusion Criteria: non-realization of any cognitive or functional assessment presence of Parkinson's Disease, Dementia and Stroke with motor sequel frequency to trainings below 70%

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dual task training<br>Dual task training | Other: Dual task training<br>* The dual task training consisted of individuals subjected to a multicomponent exercise program associated to cognitive tasks.<br>|
| Experimental: Conventional training<br>Conventional training | Other: Conventional training<br>* The conventional training consisted of individuals subjected to a multicomponent exercise program.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes on cognition after 3 months of training | Cognition was assessed by Montreal Cognitive Assessment and Mini-Mental State Examination | Assessed at baseline and after 3 months of training | 
| Changes on functional capacity after 3 months of training | Functional capacity was assessed by Timed up and go test, Timed up and go test associated to a cognitive task and sit to stand test. | Assessed at baseline and after 3 months of training | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aged, Exercise, Cognition, Functional capacity
Antipsychotic Discontinuation in High-risk Subjects

Study Overview
=================
Brief Summary
-----------------
Would be there any difference in dopamine synthesis between remitted clinical high risk subjects for psychosis and healthy control? What would happen to dopamine synthesis after antipsychotic discontinuation in clinical high risk subjects for psychosis? What about the dopamine synthesis in recurred clinical high risk subjects for psychosis after the discontinuation?

Detailed Description
-----------------
After the antipsychotic medication discontinuation, we are going to assess the changes of the biological markers

Official Title
-----------------
Antipsychotic Discontinuation in High-risk Subjects

Conditions
-----------------
Schizophrenia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed as a clinical High Risk Treated with antipsychotic drugs PSP1-5 (from SIPS criteria) <3 (severity index)for more than 6 months Had not experienced a symptomatic relapse in the 6 months Exclusion Criteria: Significant abnormality in laboratory tests History of head trauma

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Controls<br>Healthy control | |
| patients<br>clinical high risk subjects for psychosis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presynaptic dopamine synthesis in the striatum | measured with [18F]DOPA positron emission tomography | baseline |
Microcirculation in Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether cardiopulmonary bypass affects mesenteric microcirculatory function, using sublingual evaluation, in cardiac surgery.

Official Title
-----------------
Mesenteric Microcirculatory Function Study Through Sublingual Evaluation During Cardiopulmonary Bypass

Conditions
-----------------
Cardiac Disorder

Intervention / Treatment
-----------------
* Other: sublingual microcirculatory evaluation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age> 18 years old aortic valvular disease needing aortic valve replacement Exclusion Criteria: Age<18 years old emergent cardiac surgery other cardiac surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: aortic valve replacement<br> | Other: sublingual microcirculatory evaluation<br>* TNF, ICAM, syndecan-1, heparan sulfate<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Microcirculatory impairment | Mean flow index measurement and capillar density study | 36 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiopulmonary bypass, mesenteric, microcirculatory function
Strokecopilot: A Precision Medicine Tool in the Stroke Emergency

Study Overview
=================
Brief Summary
-----------------
Ischemic stroke or cerebral infarction (CI) is an immediate emergency affecting approximately 100,000 - 150,000 patients each year in France and is managed in the neurovascular intensive care unit (NICU). Recanalization treatments can prevent disability, but patients must be carefully selected. Knowledge in this field is evolving rapidly, which tends to make management more complex and personalized. In addition, the permanence of thrombolysis channels involves neurologists of all expertise. Decision support tools are desirable to enable precision medicine in stroke. Strokecopilot is a web application developed by the principal investigator. Its algorithm contextualizes the patient in a set of evidence-based medicine references (recommendations and clinical trials) and gives the result of their cross-referencing to the user to indicate theoretical indications for intravenous thrombolysis and mechanical thrombectomy.

Official Title
-----------------
Strokecopilot: A Precision Medicine Tool in the Stroke Emergency

Conditions
-----------------
Cerebrovascular Accident (CVA)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: - Adult patient (>18 years old) admitted to the thrombolysis unit of the University Hospital of Strasbourg from January 01, 2017 to December 31, 2021 Exclusion criteria: - Subjects who have expressed their opposition to the use of their data for scientific research purposes.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective analysis of thrombolysis data for the development of an algorithm to detect thrombolysis |  | Files analysed retrospectively from January 01, 2017 to December 31, 2021 will be examined | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cerebrovascular accident (CVA), Ischemic stroke, thrombolysis channels, intravenous thrombolysis, mechanical thrombectomy
Registry of Pancreatic Exocrine Insufficiency.

Study Overview
=================
Brief Summary
-----------------
A prospective, cross-sectional, observational study has been designed with the aim of the study is to evaluate the diagnosis and management of patients with pancreatic exocrine insufficiency secondary to different pancreatic diseases and conditions in clinical practice. A registry has been develop to include patients older than 18 years diagnosed with pancreatic exocrine insufficiency, sho are willing to participate in the study and sign the informed consent. Registry includes demographics, toxic habits,pharmacological therapies, underlying disease that causes pancreatic exocrine insufficiency.

Official Title
-----------------
Development of a Registry of Patients With Pancreatic Exocrine Insufficiency of Different Etiologies

Conditions
-----------------
Exocrine Pancreatic Insufficiency

Intervention / Treatment
-----------------
* Drug: Pancreatic Enzyme


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 18 years diagnosed with PEI secondary to pancreatic diseases, pancreatectomy, or gastrectomy. Willingness to participate in the study. Exclusion Criteria: Patients with pancreatic diseases without PEI. Pregnancy Known allergy to oral pancreatic enzymes Any condition avoiding adequate clinical management of PEI. Patients who are not willing to participate in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Case<br>Adult patients diagnosed with pancreatic exocrine insufficiency of any etiology | Drug: Pancreatic Enzyme<br>* Registry of pancreatic enzyme therapy prescribed to included patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dose of oral pancreatic enzymes | Dose required for symptoms relief and normalization of the nutritional status | Six months |
Myocardial Salvage and Contrast Dye Induced Nephropathy Reduction by N-Acetylcystein

Study Overview
=================
Brief Summary
-----------------
Acetylcystein is a potent antioxidans which is able to prevent contrast dye induced nephropathy in stable patients undergoing additional hydration. In primary percutaneous intervention for infarction hydration is not possible. Therefore Acetylcystein might prevent contrast dye induced nephropathy. Furthermore, it might reduce infarct size as a result of its antioxidant properties. Clinical trials are missing so far examining the effects of Acetylcystein on nephropathy and infarct size.

Official Title
-----------------
Trial to Compare Infarct Size and Occurrence of Contrast Dye Induced Nephropathy in Patients With Primary Percutaneous PCI in STEMI

Conditions
-----------------
Myocardial Infarction

Intervention / Treatment
-----------------
* Drug: Acetylcystein
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ST-elevation infarction (<12 hours) Angina Exclusion Criteria: Prior fibrinolysis Dialysis Pregnancy Lactase-reduction Glucose-galactose malabsorption Known allergy to acetylcystein

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>High-dose N-Acetylcystein during percutaneous coronary intervention and for 2 days post intervention 2 x/day | Drug: Acetylcystein<br>* high-dose N-Acetylcystein during PCI and for 2/day for 2 days<br>|
| Placebo Comparator: 2<br>Placebo (NaCl) | Drug: Placebo<br>* NaCl as placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Myocardial salvage measured by magnetic resonance imaging |  | 4 days | 
| prevention of nephropathy |  | 3 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ST-segment resolution |  | 90 min | 
| TIMI flow |  | minutes | 
| composite clinical endpoint (death, reinfarction, congestive heart failure) |  | 30 days | 
| need for dialysis |  | 4 days | 
| microvascular obstruction measured by magnetic resonance |  | 4 days | 
| infarct size measured by magnetic resonance |  | 4 days | 
| oxidative stress |  | 72 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
primary PCI, nephropathy, infarct size, infarction, ST-elevation myocardial infarction
The Effect of Midazolam on Fluid Responsiveness in Septic Patients

Study Overview
=================
Brief Summary
-----------------
Fluid resuscitation remains the foundation for septic treatment.The evaluation of fluid responsiveness has significance in volume resuscitation for septic shock patients. As the sedative which is commonly used in ICU, Midazolam is supposed to change fluid responsiveness for the pharmacological effect of venodilation. However, the hypothesis has not been certified clinically. In this research, the investigators aim to test the hypothesis that Midazolam can increase fluid responsiveness(using passive leg raising test) in septic shock patients.

Conditions
-----------------
Septic Shock

Intervention / Treatment
-----------------
* Drug: sedatives(Midazolam and Propofol)


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients are included if they meet the following inclusion criteria: Above 18 years old Endotracheal intubated and mechanical ventilated Awake, can communicate with researchers Diagnosed as septic shock. The definition of septic shock was clarified in Year 2001 ACCP/SCCM guidelines Within 24 hours after the EGDT resuscitation goals are achieved Informed consent are signed. Exclusion Criteria Under 18 years old Intra-abdominal hypertension Central nerves system dysfunction Heart failure and other cardiac dysfunction such as cardiac conduction block,acute coronary syndrome, cardiogenic shock Proof of volume overload or contradiction of fluid infusion Existence of arterial aneurysm, serious valvular disease,extensive peripheral vascular occlusion disease and insertion of artificial pacemaker

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Midazolam<br>Midazolam infused at a 0.03mg/kg loading dose ,and 0.02-0.1mg/kg.h maintenance dose to achieve Ramsay score of 4 | Drug: sedatives(Midazolam and Propofol)<br> <br> |
| Experimental: Propofol<br>Propofol infuse at a loading dose of 0.5mg/kg，and 0.5-2.0mg/kg.h maintenance dose to achieve Ramsay score of 4 | Drug: sedatives(Midazolam and Propofol)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of participants with more than 10% increase of cardiac index by passive leg raising after sedation |  | Baseline,after sedation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
septic shock, sepsis, fluid responsiveness, Midazolam, Propofol, haemodynamics
Work Pressure for Pharmacist With Home Pharmaceutical Care

Study Overview
=================
Brief Summary
-----------------
National Health Insurance Administration, Taiwan has provided a protocol for community pharmacist to offer home pharmaceutical care for the patients with high health expenditures. Since community pharmacists need to visit patients for consultation and check their medications, it has been thought to have pressure for them in various areas. This study intends to investigate the factors related to the pressure and intention for leaving this protocol. The hypothesis are that community pharmacist who works longer, has economic pressure, and longer year of practice will have higher pressure and strong intention for leaving.

Official Title
-----------------
Factors Related to Work Pressure and Turnover Intention for Pharmacists With Home Pharmaceutical Care

Conditions
-----------------
Pressure Factors, Work Load., Intention of Leaving the Service

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: community pharmacists who attend the protocol. Exclusion Criteria: community pharmacists who attend any other home pharmaceutical care projects (any types).
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pharmacists provide pharmaceutical care<br>The group is the community pharmacists who attend the protocol to provide home visit to the patients with heavy health expenditure, through pharmaceutical care approach. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intention to leave the service | community pharmacist who provides the service will have chance to fill the questionnaire. the major outcome will be his/her intention to leave the service. | up to four months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| work pressure | each community pharmacist will be asked through questionnaire regarding their work pressure related to the pharmaceutical care. | up to four months | 
| work load | each community pharmacist attends the study will provide what they though about the loading in offering pharmaceutical care. | up to four months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pharmaceutical Care, Taiwan, pharmacist, Workload, pressure
Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for Long-term Use for Chronic Obstructive Pulmonary Disease (COPD) Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of the investigation is to confirm the safety and efficacy in long-term use of Symbicort Turbuhaler in patients with Chronic obstructive pulmonary disease (COPD) under the post-marketing actual use.

Detailed Description
-----------------
Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for long-term use for COPD patients

Official Title
-----------------
Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for Long-term Use for COPD Patients

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Among patients treated with Symbicort Turbuhaler due to chronic obstructive pulmonary disease(COPD), those who received the drug for the first time.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Symbicort<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse event incidence |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical questionnaire about chronic obstructive pulmonary disease(CCQ) |  | At baseline, Week 12, Week 26, 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
long-term use, chronic obstructive pulmonary disease, Symbicort